AstraZeneca to acquire Canadian cancer drugmaker Fusion for $2bn
The transaction complements AstraZeneca’s oncology portfolio with Fusion’s pipeline of RCs, including its lead programme FPI-2265, and replaces the traditional chemotherapy and radiotherapy with more targeted treatments